BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31226332)

  • 1. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
    Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
    Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
    Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance in Mycobacterium tuberculosis clinical isolates from Brazil: phenotypic and genotypic methods.
    Miyata M; Pavan FR; Sato DN; Marino LB; Hirata MH; Cardoso RF; de Melo FA; Zanelli CF; Leite CQ
    Biomed Pharmacother; 2011 Sep; 65(6):456-9. PubMed ID: 21880463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
    Rancoita PMV; Cugnata F; Gibertoni Cruz AL; Borroni E; Hoosdally SJ; Walker TM; Grazian C; Davies TJ; Peto TEA; Crook DW; Fowler PW; Cirillo DM;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
    Zhang Z; Li T; Qu G; Pang Y; Zhao Y
    Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.
    Caleffi-Ferracioli KR; Maltempe FG; Siqueira VL; Cardoso RF
    Tuberculosis (Edinb); 2013 Nov; 93(6):660-3. PubMed ID: 24083948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study.
    Barilar I; Fernando T; Utpatel C; Abujate C; Madeira CM; José B; Mutaquiha C; Kranzer K; Niemann T; Ismael N; de Araujo L; Wirth T; Niemann S; Viegas S
    Lancet Infect Dis; 2024 Mar; 24(3):297-307. PubMed ID: 37956677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis.
    Gonzalo X; Casali N; Broda A; Pardieu C; Drobniewski F
    Int J Antimicrob Agents; 2015 Apr; 45(4):406-12. PubMed ID: 25717028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.
    Brown TS; Tang L; Omar SV; Joseph L; Meintjes G; Maartens G; Wasserman S; Shah NS; Farhat MR; Gandhi NR; Ismail N; Brust JCM; Mathema B
    Clin Infect Dis; 2024 Feb; 78(2):269-276. PubMed ID: 37874928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
    Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Millard J; Rimmer S; Nimmo C; O'Donnell M
    Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates.
    Rey-Jurado E; Tudó G; de la Bellacasa JP; Espasa M; González-Martín J
    Int J Antimicrob Agents; 2013 Mar; 41(3):278-80. PubMed ID: 23312604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
    López-Gavín A; Tudó G; Vergara A; Hurtado JC; Gonzalez-Martín J
    Int J Antimicrob Agents; 2015 Nov; 46(5):582-5. PubMed ID: 26421981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
    Imperiale BR; Zumárraga MJ; Di Giulio AB; Cataldi AA; Morcillo NS
    Int J Tuberc Lung Dis; 2013 Aug; 17(8):1088-93. PubMed ID: 23827034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
    Heyckendorf J; Andres S; Köser CU; Olaru ID; Schön T; Sturegård E; Beckert P; Schleusener V; Kohl TA; Hillemann D; Moradigaravand D; Parkhill J; Peacock SJ; Niemann S; Lange C; Merker M
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran.
    Madadi-Goli N; Ahmadi K; Kamakoli MK; Azizi M; Khanipour S; Dizaji SP; Nasehi M; Siadat SD; Fateh A; Vaziri F
    Ann Clin Microbiol Antimicrob; 2024 Apr; 23(1):36. PubMed ID: 38664815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.